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(CDC), in collaboration with partners in the cancer
research community and state health departments,
is pleased to support this series of important
articles on ‘‘Melanoma Surveillance in the United
States.’’ This supplement represents advancements
in our knowledge of melanoma incidence and
trends and provides the most comprehensive,
state-by-state examination of the status of mela-
noma cancer in the United States to date. A
common and largely preventable disease, it is
important to monitor and watch trends to identify
opportunities for action. CDC’s National Program
of Cancer Registries provides the foundation for
melanoma surveillance and offers opportunities to
ensure treatment quality and use cancer registry
data to drive decision making on policy and
systems change. These data can also be used to
guide future prevention efforts and tailor early
detection and primary prevention efforts to com-
munities with the greatest needs.
CDC has been building the science base for
chronic disease prevention and health promotion
to improve the health of Americans. This series
continues to enhance our knowledge of what works
and what more needs to be done to lessen the
burden of melanoma in the United States. The cost of
cancer extends beyond the number of lives cut short
and new diagnoses each year. Persons with mela-
noma, and their family members, friends, and care-
givers, may face physical, emotional, social, and
economic challenges as a result of their cancer
diagnosis and treatment. New analyses conducted
by CDC health economists in this supplement
identify the costs associated with melanoma to un-
derstand the impact of the disease on society and
allow us to make the business case for prevention
and policy change. CDC’s Comprehensive Cancer
Control Programs in states, territories, and tribal
organizations provide opportunities to develop andDivision of Cancer Prevention and Control, Centers for
isease Control and Prevention.
ication of this supplement to the JAAD was supported by the
ivision of Cancer Prevention and Control, Centers for Disease
ontrol and Prevention (CDC).
licts of interest: None declared.
opinions or views expressed in this supplement are those of
e authors and do not necessarily reflect the opinions,implement policy, system, and environmental
changes that can reduce exposure to ultraviolet
radiation and thereby prevent skin cancer, increase
access to quality treatment, and address the long-
term needs of cancer survivors.
This series of articles is the result of several years’
work and thoughtful consideration of awide range of
issues involving many participants. The focus on
melanoma is timely and appropriate as we press
ahead to accelerate community transformation to
translate scientific knowledge into effective public
health efforts. We appreciate the in-kind support
from all the contributors to this supplement. We are
also grateful for the guidance provided by the
project steering committee members: Umed Ajani,
Appathurai Balamurugan, David Buller, Suephy
Chen, Vivien Chen, Myles Cockburn, Alan Geller,
Karen Glanz, Jeannette Jackson-Thompson,
Ahmedin Jemal, Chris Johnson, Jessica King, Sue-
Min Lai, Mary B. Lewis, Brian Pollack, Loria Pollack,
Tom Richards, Sun Hee Rim, Mona Saraiya, Recinda
Sherman, Simple Singh, Cheryll Thomas, Julie
Townsend, Meg Watson, Hannah Weir, and Xiao-
Cheng Wu. Our gratitude also goes to editorial and
graphic services at the CDC, especially Fonda Martin
and Rick Hull. We would like to give special thanks
to SuephyChen at EmoryUniversity for dermatologic
consultation, editing, and review. The dedication and
leadership fromMegWatson andMona Saraiya of the
Division of Cancer Prevention and Control is re-
flected in this informative and important supplement.
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